A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis

BACKGROUND: Chronic inflammation is thought to be a major causative factor for the development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Tadalafil, a phosphodiesterase type 5 inhibitor (PDE5-I), which has been used for the treatment of BPH-LUTS in daily practice,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugimoto, Mikio, Zhang, Xia, Ueda, Nobufumi, Tsunemori, Hiroyuki, Taoka, Rikiya, Hayashida, Yusi, Hirama, Hiromi, Miyauchi, Yasuyuki, Matsuoka, Yuki, Naito, Hirohito, Osaki, Yu, Kekehi, Yosiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806527/
https://www.ncbi.nlm.nih.gov/pubmed/31646996
http://dx.doi.org/10.1186/s12894-019-0525-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806527/
https://www.ncbi.nlm.nih.gov/pubmed/31646996
http://dx.doi.org/10.1186/s12894-019-0525-x

Ejemplares similares